Elanco Animal Health Incorporated Capital Expenditures
Elanco Animal Health Incorporated (ELAN) reported Capital Expenditures of $84.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-05
- Elanco Animal Health Incorporated payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $33.00M, a 42.11% decline year-over-year.
- Elanco Animal Health Incorporated payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $51.00M, a 21.54% decline year-over-year.
- Elanco Animal Health Incorporated payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $62.00M, a 31.91% increase year-over-year.
- Elanco Animal Health Incorporated payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $92.00M, a 119.05% increase year-over-year.
- Elanco Animal Health Incorporated payments to acquire property, plant, and equipment for fiscal 2025 was $276.00M, a 87.76% increase from fiscal 2024.
- Elanco Animal Health Incorporated payments to acquire property, plant, and equipment for fiscal 2024 was $147.00M, a 5.00% increase from fiscal 2023.
- Elanco Animal Health Incorporated payments to acquire property, plant, and equipment for fiscal 2023 was $140.00M, a 18.13% decline from fiscal 2022.
- Elanco Animal Health Incorporated payments to acquire property, plant, and equipment for fiscal 2022 was $171.00M, a 7.55% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 3 month as first filed | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 9 month as first filed | Payments to Acquire Property, Plant, and Equipment 12 month | Payments to Acquire Property, Plant, and Equipment 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $33.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $84.00M 10-Q · filed 2026-08-05 | $146.00M derived: sum of 3 quarters · filed 2026-08-05 | $238.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $51.00M 10-Q · filed 2026-05-06 | $113.00M derived: sum of 2 quarters · filed 2026-05-06 | $205.00M derived: sum of 3 quarters · filed 2026-05-06 | $262.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $62.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $154.00M derived: sum of 2 quarters · filed 2026-02-24 | $211.00M derived: sum of 3 quarters · filed 2026-08-05 | $276.00M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $92.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $149.00M derived: sum of 2 quarters · filed 2026-08-05 | $214.00M 10-Q · filed 2025-11-05 | $261.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $57.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $122.00M 10-Q · filed 2026-08-05 | $169.00M derived: sum of 3 quarters · filed 2026-08-05 | $211.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $65.00M 10-Q · filed 2026-05-06 | $112.00M derived: sum of 2 quarters · filed 2026-05-06 | $154.00M derived: sum of 3 quarters · filed 2026-05-06 | $188.00M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $47.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $89.00M derived: sum of 2 quarters · filed 2026-02-24 | $123.00M derived: sum of 3 quarters · filed 2026-02-24 | $147.00M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $42.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $76.00M derived: sum of 2 quarters · filed 2025-11-05 | $100.00M 10-Q · filed 2025-11-05 | $141.00M derived: sum of 4 quarters · filed 2026-02-24 | |||
| 2024-06-30 | $34.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $58.00M 10-Q · filed 2025-08-07 | $99.00M derived: sum of 3 quarters · filed 2026-02-24 | $132.00M derived: sum of 4 quarters · filed 2026-02-24 | |||
| 2024-03-31 | $24.00M 10-Q · filed 2025-05-07 | $65.00M derived: sum of 2 quarters · filed 2026-02-24 | $98.00M derived: sum of 3 quarters · filed 2026-02-24 | $140.00M derived: sum of 4 quarters · filed 2026-02-24 | |||
| 2023-12-31 | $41.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $74.00M derived: sum of 2 quarters · filed 2026-02-24 | $116.00M derived: sum of 3 quarters · filed 2026-02-24 | $140.00M 10-K · filed 2026-02-24 | |||
| 2023-09-30 | $33.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $75.00M derived: sum of 2 quarters · filed 2024-11-07 | $99.00M 10-Q · filed 2024-11-07 | $199.00M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-06-30 | $42.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $66.00M 10-Q · filed 2024-08-08 | $166.00M derived: sum of 3 quarters · filed 2025-02-25 | $192.00M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-03-31 | $24.00M 10-Q · filed 2024-05-08 | $20.00M 10-Q · filed 2023-05-09 | $124.00M derived: sum of 2 quarters · filed 2025-02-25 | $150.00M derived: sum of 3 quarters · filed 2025-02-25 | $176.00M derived: sum of 4 quarters · filed 2025-02-25 | ||
| 2022-12-31 | $100.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $126.00M derived: sum of 2 quarters · filed 2025-02-25 | $152.00M derived: sum of 3 quarters · filed 2025-02-25 | $171.00M 10-K · filed 2025-02-25 | $137.00M 10-K · filed 2023-03-01 | ||
| 2022-09-30 | $26.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $52.00M derived: sum of 2 quarters · filed 2022-11-08 | $71.00M 10-Q · filed 2022-11-08 | $170.00M derived: sum of 4 quarters · filed 2024-02-26 | |||
| 2022-06-30 | $26.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $45.00M 10-Q · filed 2022-08-08 | $144.00M derived: sum of 3 quarters · filed 2024-02-26 | $169.00M derived: sum of 4 quarters · filed 2024-02-26 | |||
| 2022-03-31 | $19.00M 10-Q · filed 2023-05-09 | $118.00M derived: sum of 2 quarters · filed 2024-02-26 | $143.00M derived: sum of 3 quarters · filed 2024-02-26 | $160.00M derived: sum of 4 quarters · filed 2024-02-26 | |||
| 2021-12-31 | $99.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $124.00M derived: sum of 2 quarters · filed 2024-02-26 | $141.00M derived: sum of 3 quarters · filed 2024-02-26 | $159.00M 10-K · filed 2024-02-26 | $126.00M 10-K · filed 2022-02-28 | ||
| 2021-09-30 | $25.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $42.00M derived: sum of 2 quarters · filed 2022-11-08 | $60.00M 10-Q · filed 2022-11-08 | $179.00M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-06-30 | $17.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $35.00M 10-Q · filed 2022-08-08 | $154.00M derived: sum of 3 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | $18.00M 10-Q · filed 2022-05-09 | $137.00M derived: sum of 2 quarters · filed 2023-03-01 | |||||
| 2020-12-31 | $119.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $135.00M 10-K · filed 2023-03-01 | $134.60M 10-K · filed 2021-03-01 | ||||
| 2020-09-30 | $16.00M 10-Q · filed 2021-11-05 | $16.20M 10-Q · filed 2020-11-06 | |||||
| 2020-03-31 | $13.00M 10-Q · filed 2021-05-07 | $12.60M 10-Q · filed 2020-05-07 | $103.20M derived: sum of 2 quarters · filed 2022-02-28 | $101.20M derived: sum of 3 quarters · filed 2022-02-28 | $125.00M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2019-12-31 | $90.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $88.20M derived: sum of 2 quarters · filed 2022-02-28 | $112.00M derived: sum of 3 quarters · filed 2022-02-28 | $140.00M 10-K · filed 2022-02-28 | $140.40M 10-K · filed 2020-02-28 | ||
| 2019-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $21.80M derived: sum of 2 quarters · filed 2020-11-06 | $49.80M 10-Q · filed 2020-11-06 | $86.00M 10-Q · filed 2019-11-08 | $110.00M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-06-30 | $23.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $51.80M 10-Q · filed 2020-07-30 | $112.00M derived: sum of 3 quarters · filed 2021-03-01 | $129.80M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2019-03-31 | $28.00M 10-Q · filed 2020-05-07 | $88.20M derived: sum of 2 quarters · filed 2021-03-01 | $106.00M derived: sum of 3 quarters · filed 2021-03-01 | $129.80M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2018-12-31 | $60.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $78.00M derived: sum of 2 quarters · filed 2021-03-01 | $101.80M derived: sum of 3 quarters · filed 2021-03-01 | $134.50M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $17.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $41.60M derived: sum of 2 quarters · filed 2019-11-08 | $74.30M 10-Q · filed 2019-11-08 | $141.20M derived: sum of 4 quarters · filed 2020-02-28 | |||
| 2018-06-30 | $23.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $56.50M 10-Q · filed 2019-08-13 | $123.40M derived: sum of 3 quarters · filed 2020-02-28 | ||||
| 2018-03-31 | $32.70M 10-Q · filed 2019-05-14 | $99.60M derived: sum of 2 quarters · filed 2020-02-28 | |||||
| 2017-12-31 | $66.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $98.60M 10-K · filed 2020-02-28 | |||||
| 2017-09-30 | $31.70M 10-Q · filed 2018-11-08 | ||||||
| 2016-12-31 | $110.30M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |